Screener
Viking Therapeutics VKTX Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Viking Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Viking Therapeutics’s 10-Q, filed April 30, 2026.
- Filed
- Apr 29, 2026, 9:50 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-193315
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cash flows from investing activities | ||
| Purchases of investments | (72,437) | (232,614) |
| Proceeds from maturities of investments | 126,626 | 295,859 |
| Net cash provided by investing activities | 54,189 | 63,245 |
| Cash flows from financing activities | ||
| Proceeds from exercises of stock options and other stock issuances | 450 | 349 |
| ATM offering, net of fees | 11,627 | — |
| Net cash provided by financing activities | 12,077 | 349 |
Item 1. Financial Statements
FAQ
- What is Viking Therapeutics's investing cash flow?
- Viking Therapeutics (VKTX) reported investing cash flow of $54.19M in Q1 2026.
- How has Viking Therapeutics's investing cash flow changed year-over-year?
- Viking Therapeutics's investing cash flow decreased by 14.3% year-over-year, from $63.25M to $54.19M.
- What is the long-term trend for Viking Therapeutics's investing cash flow?
- Over 2 years (2021 to 2025), Viking Therapeutics's investing cash flow has grown at a 199.9% compound annual growth rate (CAGR), from $37.96M to $341.39M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Viking Therapeutics's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude